MX2017002853A - Nueva composicion farmaceutica para la prevencion y/o el tratamiento de la incontinencia urinaria. - Google Patents

Nueva composicion farmaceutica para la prevencion y/o el tratamiento de la incontinencia urinaria.

Info

Publication number
MX2017002853A
MX2017002853A MX2017002853A MX2017002853A MX2017002853A MX 2017002853 A MX2017002853 A MX 2017002853A MX 2017002853 A MX2017002853 A MX 2017002853A MX 2017002853 A MX2017002853 A MX 2017002853A MX 2017002853 A MX2017002853 A MX 2017002853A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
urinary incontinence
treatment
novel pharmaceutical
incontinence prevention
Prior art date
Application number
MX2017002853A
Other languages
English (en)
Inventor
Mori Shinobu
Inamura Hiroko
Hirata Takuya
Kajihara Yusuke
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2017002853A publication Critical patent/MX2017002853A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El problema a resolver por la presente invención es proporcionar una nueva composición farmacéutica para la prevención y/o el tratamiento de la incontinencia urinaria, que difiere de los fármacos convencionales. La presente invención proporciona un agente terapéutico para la prevención y/o el tratamiento de la incontinencia urinaria que tiene 1-[2-({[trans-3-fluoro-1-(3-fluor opiridin-2-il) ciclobutil]metil}amino)pirimidin-5-il]-1H-pirrol-3- carboxamida o una sal de la misma, como ingrediente activo.
MX2017002853A 2014-09-09 2015-09-09 Nueva composicion farmaceutica para la prevencion y/o el tratamiento de la incontinencia urinaria. MX2017002853A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014183434 2014-09-09
PCT/JP2015/075567 WO2016039367A1 (ja) 2014-09-09 2015-09-09 尿失禁予防用及び／又は治療用新規医薬組成物

Publications (1)

Publication Number Publication Date
MX2017002853A true MX2017002853A (es) 2018-01-12

Family

ID=55459111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002853A MX2017002853A (es) 2014-09-09 2015-09-09 Nueva composicion farmaceutica para la prevencion y/o el tratamiento de la incontinencia urinaria.

Country Status (18)

Country Link
US (1) US9987279B2 (es)
EP (1) EP3192512B1 (es)
JP (1) JP6573618B2 (es)
KR (1) KR102460731B1 (es)
CN (1) CN106687115B (es)
AU (1) AU2015313221B2 (es)
BR (1) BR112017004505A2 (es)
CA (1) CA2957804C (es)
ES (1) ES2750751T3 (es)
IL (1) IL250919B (es)
MX (1) MX2017002853A (es)
PH (1) PH12017500436A1 (es)
PL (1) PL3192512T3 (es)
PT (1) PT3192512T (es)
RU (1) RU2738886C9 (es)
SG (1) SG11201701019UA (es)
WO (1) WO2016039367A1 (es)
ZA (1) ZA201701671B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
TWI773118B (zh) 2016-02-12 2022-08-01 美商細胞動力學股份有限公司 四氫異喹啉衍生物
EP3732166A4 (en) * 2017-12-26 2021-09-01 Cytokinetics, Incorporated PROCESS FOR THE MANUFACTURING OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF
CN116635378A (zh) 2020-11-06 2023-08-22 赛特凯恩蒂克公司 二环1,4-二氮杂环庚酮和其治疗用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095359A1 (en) 2004-03-05 2005-10-13 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
US20080009538A1 (en) * 2005-03-21 2008-01-10 Phil Skolnick Methods and compositions for the treatment of urinary incontinence
JP2007176933A (ja) * 2005-11-29 2007-07-12 Tanabe Seiyaku Co Ltd 医薬組成物
JP2007290970A (ja) * 2006-04-21 2007-11-08 Astellas Pharma Inc 腹圧性及び混合型尿失禁治療剤
CA2672591A1 (en) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Treating agent of uropathy
US20100240697A1 (en) 2007-11-02 2010-09-23 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
JP5553547B2 (ja) 2009-07-14 2014-07-16 俊一 梶岡 トロポニン含有医薬組成物
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
CN108553467A (zh) 2012-04-02 2018-09-21 赛特凯恩蒂克公司 改善膈肌功能的方法
KR102163931B1 (ko) 2012-04-11 2020-10-12 싸이토키네틱스, 인코포레이티드 골격근 피로에 대한 저항을 개선

Also Published As

Publication number Publication date
ES2750751T3 (es) 2020-03-27
IL250919A0 (en) 2017-04-30
RU2738886C2 (ru) 2020-12-18
WO2016039367A1 (ja) 2016-03-17
US9987279B2 (en) 2018-06-05
RU2017111848A3 (es) 2019-07-17
KR102460731B1 (ko) 2022-10-28
EP3192512A4 (en) 2018-02-07
EP3192512B1 (en) 2019-08-14
RU2738886C9 (ru) 2021-12-06
JPWO2016039367A1 (ja) 2017-06-15
PH12017500436A1 (en) 2017-07-31
ZA201701671B (en) 2019-06-26
IL250919B (en) 2019-10-31
PL3192512T3 (pl) 2020-03-31
CA2957804A1 (en) 2016-03-17
PT3192512T (pt) 2019-10-29
SG11201701019UA (en) 2017-03-30
AU2015313221A1 (en) 2017-03-09
CN106687115B (zh) 2019-07-19
RU2017111848A (ru) 2018-10-08
EP3192512A1 (en) 2017-07-19
JP6573618B2 (ja) 2019-09-11
CA2957804C (en) 2023-04-04
AU2015313221B2 (en) 2019-11-21
CN106687115A (zh) 2017-05-17
US20170273979A1 (en) 2017-09-28
KR20170045353A (ko) 2017-04-26
BR112017004505A2 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
PH12017500436A1 (en) Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence
JOP20190186A1 (ar) مركب كينازولين
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
SG11202106160WA (en) Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient
MX2023002507A (es) Inhibidores de cd73.
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
PH12018501976A1 (en) Arginase inhibitors and their therapeutic applications
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
NZ788133A (en) Cd73 inhibitors
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PH12016501527B1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
CR20210532A (es) Protacs que degradan el receptor de estrógeno
EP3541943A4 (en) MICRO-ORGANISM FOR ADMINISTERING A MEDICINAL PRODUCT FOR THE TREATMENT OF A GASTROINTESTINAL DISEASE, WHICH EXPRESSES AND SECRETS P8 PROTEIN, AND PHARMACEUTICAL COMPOSITION CONSISTING OF THIS MICRO-ORGANISM FOR THE PREVENTION OR TREATMENT OF A GASTROINTESTINAL DISEASE
EP4000609A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASES
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
SG11202106163RA (en) Pharmaceutical composition for prevention or treatment of cancer comprising lactobacillus sakei wikim30 as active ingredient
PH12017501668A1 (en) Bace1 inhibitors
EP3785715A4 (en) Pharmaceutical composition comprising ibrutinib as effective ingredient for preventing or treating degenerative brain disease
EP3632447A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF BONE DISEASE
EP3677267A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF TUMORS, METHOD AND USES THEREOF
EP3659584A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISORDERS, CONTAINING HDL-APOM-S1P AS ACTIVE INGREDIENT
EP3610879A4 (en) COMPOSITION OF TREATMENT AND / OR PREVENTION OF ALZHEIMER'S DISEASE
IL288242A (en) Nitrogen heteroaryl compounds, preparations containing alt compounds and their use for cancer treatment

Legal Events

Date Code Title Description
FG Grant or registration